1. National Institute for Health Research. Imlifidase for kidney transplantation in highly sensitised patients with chronic kidney disease (NIHR health technology briefing). 2019. http://www.io.nihr.ac.uk/wp-content/uploads/2019/07/11428-Imlifidase-for-Kidney-Transplantation-V1.0-JUL2019-NONCONF.pdf. Accessed 21 Sept 2020.
2. Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated NK cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation. 2019. https://doi.org/10.1097/tp.0000000000003023.
3. Sethi S, Choi J, Toyoda M, et al. Desensitization: overcoming the immunologic barriers to transplantation. J Immunol Res. 2017. https://doi.org/10.1155/2017/6804678.
4. Hansa Biopharma AB. The EU Commission grants conditional approval for Idefirix™ (imlifidase) in highly sensitized kidney transplant patients in the European Union [media release]. 26 Aug 2020. http://www.hansabiopharma.com.
5. European Medicines Agency. Idefirix (imlifidase): EU summary of product characteristics. 2020. https://www.ema.europa.eu/en/documents/product-information/idefirix-epar-product-information_en.pdf. Accessed 21 Sept 2020.